CN105250366B - 香青兰提取物及其制备方法和用途 - Google Patents
香青兰提取物及其制备方法和用途 Download PDFInfo
- Publication number
- CN105250366B CN105250366B CN201510652848.7A CN201510652848A CN105250366B CN 105250366 B CN105250366 B CN 105250366B CN 201510652848 A CN201510652848 A CN 201510652848A CN 105250366 B CN105250366 B CN 105250366B
- Authority
- CN
- China
- Prior art keywords
- ethanol
- moldavica dragonhead
- percent
- extract
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000284 extract Substances 0.000 title claims abstract description 91
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000000605 extraction Methods 0.000 title claims description 66
- 244000179525 Dracocephalum moldavica Species 0.000 title claims description 5
- 235000010700 Dracocephalum moldavica Nutrition 0.000 title claims description 5
- 241001529849 Dracocephalum Species 0.000 claims abstract description 173
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 400
- 235000019441 ethanol Nutrition 0.000 claims description 131
- 239000000243 solution Substances 0.000 claims description 119
- 239000000843 powder Substances 0.000 claims description 69
- 239000000463 material Substances 0.000 claims description 63
- 238000010992 reflux Methods 0.000 claims description 62
- 238000010828 elution Methods 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 58
- 239000011259 mixed solution Substances 0.000 claims description 56
- 239000003480 eluent Substances 0.000 claims description 54
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 51
- 239000011347 resin Substances 0.000 claims description 35
- 229920005989 resin Polymers 0.000 claims description 35
- 238000001035 drying Methods 0.000 claims description 32
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 28
- 238000005406 washing Methods 0.000 claims description 26
- 238000001179 sorption measurement Methods 0.000 claims description 23
- NLZCOTZRUWYPTP-MIUGBVLSSA-N 5-hydroxy-2-(4-methoxyphenyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLZCOTZRUWYPTP-MIUGBVLSSA-N 0.000 claims description 19
- NLZCOTZRUWYPTP-UHFFFAOYSA-N acacetin-7-O-beta-D-galactoside Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(CO)O1 NLZCOTZRUWYPTP-UHFFFAOYSA-N 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- GWOKWCRSUJQOMD-UHFFFAOYSA-N tilianin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC=C2OC1C(O)C(O)C(O)C(CO)O1 GWOKWCRSUJQOMD-UHFFFAOYSA-N 0.000 claims description 19
- 208000029078 coronary artery disease Diseases 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 14
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 14
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 14
- 239000008367 deionised water Substances 0.000 claims description 13
- 229910021641 deionized water Inorganic materials 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- XCKMDTYMOHXUHG-UHFFFAOYSA-N Diosmetin 7-O-beta-D-glucuronopyranoside Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2OC1C(O)C(O)C(O)C(C(O)=O)O1 XCKMDTYMOHXUHG-UHFFFAOYSA-N 0.000 claims description 8
- 239000003463 adsorbent Substances 0.000 claims description 7
- 229930003935 flavonoid Natural products 0.000 claims description 6
- 150000002215 flavonoids Chemical class 0.000 claims description 6
- 235000017173 flavonoids Nutrition 0.000 claims description 6
- VSUOKLTVXQRUSG-ZFORQUDYSA-N luteolin 7-O-beta-D-glucosiduronic acid Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 VSUOKLTVXQRUSG-ZFORQUDYSA-N 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- JBFOLLJCGUCDQP-ZFORQUDYSA-N Apigenin 7-glucuronide Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 JBFOLLJCGUCDQP-ZFORQUDYSA-N 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- GTDSSCNJWWPJHR-UHFFFAOYSA-N apigenin 7-O-beta-D-glucuronide Natural products OC1C(Oc2ccc3C(=O)C=C(Oc3c2O)c4ccc(O)cc4)OC(C(O)C1O)C(=O)O GTDSSCNJWWPJHR-UHFFFAOYSA-N 0.000 claims description 4
- JBFOLLJCGUCDQP-UHFFFAOYSA-N scutellarin A Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 JBFOLLJCGUCDQP-UHFFFAOYSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 14
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 13
- 229930003944 flavone Natural products 0.000 abstract description 13
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 13
- 235000011949 flavones Nutrition 0.000 abstract description 13
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 13
- 241000700159 Rattus Species 0.000 abstract description 12
- 239000008187 granular material Substances 0.000 abstract description 12
- 208000027418 Wounds and injury Diseases 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 5
- 208000014674 injury Diseases 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract description 4
- 150000008156 D-glucuronides Chemical class 0.000 description 25
- 239000007864 aqueous solution Substances 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510652848.7A CN105250366B (zh) | 2015-10-10 | 2015-10-10 | 香青兰提取物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510652848.7A CN105250366B (zh) | 2015-10-10 | 2015-10-10 | 香青兰提取物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105250366A CN105250366A (zh) | 2016-01-20 |
CN105250366B true CN105250366B (zh) | 2020-03-13 |
Family
ID=55090502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510652848.7A Expired - Fee Related CN105250366B (zh) | 2015-10-10 | 2015-10-10 | 香青兰提取物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105250366B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106749455B (zh) * | 2015-11-24 | 2019-11-08 | 石河子大学医学院第一附属医院 | 刺槐素-7-o-葡萄糖醛酸苷的制备方法 |
CN107586311B (zh) * | 2017-07-25 | 2018-10-09 | 贵州维康子帆药业股份有限公司 | 酢浆草中提取刺槐素-6-C-β-D-葡萄糖苷的方法 |
RU2695328C1 (ru) * | 2018-09-25 | 2019-07-23 | Федеральное государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт лекарственных и ароматических растений (ФГБНУ ВИЛАР) | СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СУБСТАНЦИЙ ИЗ ЗМЕЕГОЛОВНИКА МОЛДАВСКОГО (Dracocephalum moldavica L.) |
CN109810158B (zh) * | 2019-03-01 | 2021-06-11 | 新疆维吾尔自治区药物研究所 | 香叶木素-7-o-葡萄糖醛酸苷的制备方法 |
CN113633675A (zh) * | 2021-09-28 | 2021-11-12 | 新疆维吾尔自治区药物研究所 | 香青兰提取物在制备抗心脏毒性作用药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1488638A (zh) * | 2002-10-10 | 2004-04-14 | 上海海天医药科技开发有限公司 | 淫羊藿总黄酮的提取方法及其提取物所制成的产品 |
CN101219161A (zh) * | 2007-12-25 | 2008-07-16 | 新疆维吾尔自治区药物研究所 | 香青兰提取物和香青兰滴丸及其生产方法 |
-
2015
- 2015-10-10 CN CN201510652848.7A patent/CN105250366B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1488638A (zh) * | 2002-10-10 | 2004-04-14 | 上海海天医药科技开发有限公司 | 淫羊藿总黄酮的提取方法及其提取物所制成的产品 |
CN101219161A (zh) * | 2007-12-25 | 2008-07-16 | 新疆维吾尔自治区药物研究所 | 香青兰提取物和香青兰滴丸及其生产方法 |
Non-Patent Citations (3)
Title |
---|
于宁等.香青兰提取物中苯丙素类和黄酮类3个化合物的含量测定.《中国药学杂志》.2015,第50卷(第13期),第1138页第1段、第1139页左栏第1段、第1节、第2.1.1小节、第1141页表3. * |
维药香青兰研究新进展;翁剑锋等;《江西中医学院学报》;20110430;第23卷(第2期);第81-84页 * |
香青兰提取物中苯丙素类和黄酮类3个化合物的含量测定;于宁等;《中国药学杂志》;20150731;第50卷(第13期);第1138页第1段、第1139页左栏第1段、第1节、第2.1.1小节、第1141页表3 * |
Also Published As
Publication number | Publication date |
---|---|
CN105250366A (zh) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105250366B (zh) | 香青兰提取物及其制备方法和用途 | |
JP5675839B2 (ja) | ヒマワリ抽出物を含む医薬組成物、その調製方法及び使用 | |
UA81124C2 (en) | Composition for heart disease treatment based on extracts of radix salviae and panax notogingseng roots, method to prepare and uses thereof | |
CN107648430A (zh) | 一种含延龄草甾体皂苷类有效成分胶囊制剂的制备方法及其在制备各类药物中的应用 | |
CN104435034B (zh) | 一种三七总皂苷及其制备方法 | |
KR100529793B1 (ko) | 솔잎 추출물 및 이것의 용도 | |
JP2002538214A (ja) | 心血管疾病治療用薬剤組成物及びその製造方法 | |
WO2018133563A1 (zh) | 一种人参属植物提取物及其药物组合物和应用 | |
CN103977180B (zh) | 一种具有抗抑郁作用的中药物质组方及其制备方法与应用 | |
CN100467025C (zh) | 积雪草总苷、积雪草苷或羟基积雪草苷在制备防治心、脑血管疾病药物中的用途 | |
CN100377731C (zh) | 一种中药及其制备方法和用途 | |
CN1698717B (zh) | 一种中药复方脂肪乳注射液及其制备方法 | |
CN101974011B (zh) | 一种具有药用活性的新化合物灯盏细辛酸甲酯 | |
CN101703561A (zh) | 一种治疗骨质疏松症的杜仲有效部位及其制备方法 | |
CN101428050A (zh) | 一种用于治疗血栓、心脑血管系统疾病的活性组合物 | |
CN1994277B (zh) | 一种丹参丹酚酸a固体制剂及其制备方法 | |
CN102670865A (zh) | 红葱的活性成分提取工艺 | |
CN113384641A (zh) | 用于治疗冠心病的小红蒜有效部位的提取纯化方法及其产品和应用 | |
CN101974012B (zh) | 一种具有药用活性的新化合物灯盏细辛酸乙酯 | |
CN101176751B (zh) | 丹参和桂枝的药物组合物 | |
CN110448651A (zh) | 一种治疗肝病的藏中药组合物的制备方法、该组合物及包含其的颗粒剂 | |
CN1927289A (zh) | 一种治疗糖尿病及糖耐量低减的药物组合物及制备方法 | |
KR20040043707A (ko) | 인진쑥, 애엽, 유근피, 적양, 오가피, 대두 lph펩타이드, 백석목, 메밀을 주성분으로 함유하는 숙취제거, 간염, 간암 치료의 의약 조성물 | |
CN113398186B (zh) | 一种紫花地丁提取物及其制备方法和应用 | |
CN101974010B (zh) | 一种具有药用活性的新化合物灯盏细辛酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xing Jianguo Inventor after: He Chenghui Inventor after: Yu Ning Inventor after: Zheng Ruifang Inventor after: Liu Xuanlin Inventor after: Ruxian Guli. Yiming Inventor before: Xing Jianguo Inventor before: He Chenghui Inventor before: Yu Ning Inventor before: Jiang Wen Inventor before: Liu Xuanlin Inventor before: Ruxian Guli. Yiming |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200313 |